-
Event to be held in Chicago, location of 2014 American Heart
Association Scientific Sessions
-
Webcast on Monday, November 17, 2014 at 7:30 p.m. Central Time/8:30
p.m. Eastern Time
ANN ARBOR, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical
company focused on developing and commercializing first-in-class, oral
low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies
for the treatment of hypercholesterolemia and other cardiometabolic risk
markers, today announced it will host an investor event and live webcast
to discuss the ETC-1002 development program, including the Phase 2b
ETC-1002-008 results announced last month. Perspectives will be provided
by featured speaker Mark E. McGovern, M.D., FACC, former executive vice
president, medical affairs, and chief medical officer of KOS
Pharmaceuticals; Tim M. Mayleben, president and chief executive officer
of Esperion; and members of the Esperion management team. The event will
take place on Monday, November 17, 2014 at 7:30 p.m. Central Time/8:30
p.m. Eastern Time in Chicago, IL, coinciding with the American Heart
Association Scientific Sessions.
The event can be accessed by dialing (877) 831-3840 (domestic) or (253)
237-1184 (international) five minutes prior to the start of the event
and providing access code 34444121. A live, listen-only webcast of the
presentation can be accessed on the investor relations section of the
Esperion website at www.esperion.com.
A webcast replay of the presentation will be available approximately one
hour after completion and will be archived on the Company's website.
Esperion's Commitment to Cardiometabolic Disease
Esperion is committed to improving the lives of patients with
cardiometabolic diseases. The Esperion team leverages its understanding
of, and experience with, key biological pathways to discover and develop
innovative therapies for the treatment of patients with
hypercholesterolemia who have uncontrolled cholesterol levels despite
the use of currently available therapies. Esperion has assembled a
portfolio of programs including one product candidate in late-stage
clinical evaluation (ETC-1002) and two pre-clinical product candidates.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is an emerging pharmaceutical company
focused on developing and commercializing first-in-class, oral,
LDL-cholesterol lowering therapies for the treatment of patients with
hypercholesterolemia and other cardiometabolic risk markers. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule designed to lower LDL-cholesterol
levels and avoid the side effects associated with therapies currently
available for lowering LDL-cholesterol. ETC-1002 is being developed for
patients with hypercholesterolemia, including those with a history of
statin intolerance. For more information, please visit www.esperion.com
and follow us on Twitter at https://twitter.com/EsperionInc.
Media Contact:
W2O Group
Elliot Fox
212.257.6724
efox@w2ogroup.com
or
Investor
Contact:
Esperion Therapeutics, Inc.
Mindy Lowe
734.887.3903
mlowe@esperion.com
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media